buyModerate
Raju Mohan bought $960k of VTYX
CEO AND PRESIDENT at Ventyx Biosciences, Inc.. 500,000 shares at an average of $1.92, traded Nov 22, 2024, filed Nov 25, 2024.
Conviction score
55Value
$960k
500,000 shares
Holdings after
2,175,028
+30% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +24Trade size$960k at market
- +6Relative to holdingsHoldings up 30%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-027673, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 22, 2024 | POpen-market purchase Common Stock | +238,248 | $1.83 | $435k | 1,913,276 | Nov 25, 2024 |
| Nov 25, 2024 | POpen-market purchase Common Stock | +261,752 | $2.01 | $525k | 2,175,028 | Nov 25, 2024 |
Related signals
Other insiders at Ventyx Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | Ventyx Biosciences, Inc. | Raju Mohan CEO AND PRESIDENT | $365k 47,345 shares | -2% | |
| 18Weak | Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $98k 12,675 shares | -3% | |
| 15Weak | VTYXsell Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $2,019 1,887 shares | -0% | |
| 22Weak | VTYXsell Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $50k 21,119 shares | -4% | |
| 37Weak | VTYXbuy Ventyx Biosciences, Inc. | Sheila Gujrathi director | $301k 130,000 shares | - | |
| 5Weak | VTYXsell Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $30k 13,161 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.